Introduction
heart failure, atherosclerosis
ENDOTHELIAL DYSFUNCTION, ATHEROSCLEROSIS, EVENTS, HEART FAILURE, TYPE 2 DIABETES
Sodium glucose cotransporter 2 (SGLT2) inhibitors are oral glucose medicines that lower glucose levels by reducing the renal reabsorption of glucose. Some meta-analyses and large clinical trials have shown that SGLT2 inhibitors reduce cardiovascular events in patients with type 2 diabetes and reduced the rate of hospitalization for heart failure in patients with heart failure [Endothelial dysfunction is regarded as the first stage in the etiology of atherosclerosis and plays a significant role in the progression of atherosclerosis, leading to cardiovascular issues [The PROTECT study was a multicenter prospective study designed to test the inhibitory impact of an SGLT2 inhibitor on the development of atherosclerosis based on intima-media thickness over a 24-month follow-up period [